<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848718</url>
  </required_header>
  <id_info>
    <org_study_id>2206-003</org_study_id>
    <secondary_id>2009_547</secondary_id>
    <nct_id>NCT00848718</nct_id>
  </id_info>
  <brief_title>A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (2206-003 AM5)</brief_title>
  <official_title>A Phase I Dose Escalation Study of MK-2206 in Combination With Standard Doses of Selected Chemotherapies or Targeted Agents in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and tolerability of several dose levels of
      MK-2206 in combination with chemotherapy and targeted therapy agents in participants with
      locally advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (One cycle = 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of each of the three combinations</measure>
    <time_frame>Cycle 1 (One cycle = 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration of MK-2206 (Cmax)</measure>
    <time_frame>Cycle 1 and Cycle 2 (One cycle = 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration of MK-2206 (Tmax)</measure>
    <time_frame>Cycle 1 and Cycle 2 (One cycle = 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum plasma concentration of MK-2206 (Ctrough)</measure>
    <time_frame>Cycle 1 and Cycle 2 (One cycle = 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the MK-2206 concentration versus time curve (AUC)</measure>
    <time_frame>Cycle 1 and Cycle 2 (One cycle = 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who had a tumor response, according to standard RECIST (Response Evaluation Criteria in Solid Tumors) criteria</measure>
    <time_frame>Tumor assessments will be performed at baseline and on Day 1 of every other cycle of treatment (every 6 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Locally Advanced, Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>MK-2206 + carboplatin + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-2206 combined with carboplatin and paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-2206 + docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-2206 combined with docetaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-2206 + erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-2206 combined with erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2206 combined with carboplatin + paclitaxel</intervention_name>
    <description>MK-2206 given by mouth on days 1, 3, 5, and 7 of the 21 day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 given by mouth on Day 1 of the 21 day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg). On Day 1 of each 21 Day cycle, carboplatin + paclitaxel is given intravenously.</description>
    <arm_group_label>MK-2206 + carboplatin + paclitaxel</arm_group_label>
    <other_name>Paraplatin, Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2206 combined with docetaxel</intervention_name>
    <description>MK-2206 given by mouth on days 1, 3, 5, and 7 of the 21 day cycle (either 45 mg or 60 mg) (this dosing schedule is no longer enrolling). MK-2206 given by mouth on Day 1 of the 21 day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg). On day 1 of each 21 day cycle, docetaxel is given intravenously. In this treatment arm, an oral corticosteroid is to be taken by mouth every day.</description>
    <arm_group_label>MK-2206 + docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2206 combined with erlotinib</intervention_name>
    <description>MK-2206 given by mouth every other day (30 mg, 45 mg or 60 mg) OR MK-2206 given by mouth on Days 1, 8, and 15 of the 21 day cycle (90 mg, 135 mg, or 200 mg). In addition, erlotinib is given daily by mouth in a continuous 21 day cycle for the duration of the study.</description>
    <arm_group_label>MK-2206 + erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Participants must have locally advanced or metastatic solid tumors.

          -  Participant is male or female greater than or equal to 18 years of age.

          -  Participant must have a performance status less than or equal to 1 on the Eastern
             Cooperative Oncology Group (ECOG) Performance Scale

          -  Female participants of childbearing potential has a negative serum or urine pregnancy
             test within 72 hours prior to receiving the first dose of study medication.

          -  Participants in the MK-2206 + carboplatin/paclitaxel and MK-2206 + docetaxel treatment
             arms will be limited to no more than 3 prior cytotoxic therapies for metastatic or
             recurrent diseases.

          -  Participant is able to swallow capsules and has no surgical or anatomical condition
             that will prevent the Participant from swallowing.

        Exclusion Criteria:

          -  Participant has had chemotherapy, radiotherapy or biological therapy within 4 weeks.

          -  Participants must be least 4 weeks post-surgery and do not expect major surgery in the
             study duration.

          -  Participant is currently participating or has participated in a study with an
             investigational compound or device within 30 days.

          -  Participant has known active central nervous system (CNS) metastases and/or
             carcinomatous meningitis.

          -  Participant with a primary central nervous system tumor.

          -  Participant has known hypersensitivity to the components of study drug.

          -  Participant has a history or current evidence of heart disease.

          -  Participant has evidence of clinically significant bradycardia (slow heart rate).

          -  Participant has uncontrolled high blood pressure.

          -  Participant at significant risk for hypokalemia (low potassium levels).

          -  Participant is a known diabetic

          -  Participant has known psychiatric or substance abuse disorders.

          -  Participant is a user of illicit drugs.

          -  Participant is pregnant or breastfeeding.

          -  Participant is Human Immunodeficiency Virus (HIV) positive.

          -  Participant has known history of Hepatitis B or C or active Hepatitis A.

          -  Participant has symptomatic ascites or pleural effusion.

          -  Participant is receiving treatment with oral corticosteroids.

          -  Participant is using a potent cytochrome P(450) 3A4 (CYP3A4) inhibitor or inducer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumors, cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

